• Explore /
  • Poster
  • / Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.

Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.

Abstract Poster

Authors

null

Cyrille Touzeau

Centre Hospitalier Universitaire, Nantes, France

Cyrille Touzeau , Philippe Moreau , Aurore Perrot , Cyrille Hulin , Mamoun Dib , Mourad Tiab , Denis Caillot , Thierry Facon , Xavier Leleu , Niels W.C.J. van de Donk , Annemiek Broijl , Sonja Zweegman , Mark-David Levin , Michel Delforge , Lixia Pei , Veronique Vanquickelberghe , Carla De Boer , Tobias Kampfenkel , Jessica Vermeulen , Pieter Sonneveld

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT02541383

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8538)

DOI

10.1200/JCO.2020.38.15_suppl.8538

Abstract #

8538

Poster Bd #

438

Abstract Disclosures

Similar Posters

First Author: Herve Avet-Loiseau

First Author: Michael A. Thompson

First Author: Samer Tabchi

First Author: Jule Franve Vasquez Chavez